These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24165429)

  • 1. The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.
    Bhargava A; Gleason S; Vaughan AG; Johnson JF; Yarlagadda KV
    Int J Clin Pract; 2013 Nov; 67(11):1151-8. PubMed ID: 24165429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
    King AB; Armstrong DU
    Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD
    Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
    Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of an optimal response to pioglitazone in terms of HDL-cholesterol.
    Kabeya Y; Tomita M; Asai Y; Katsuki T; Oikawa Y; Meguro S; Shimada A; Atsumi Y
    Intern Med; 2011; 50(8):825-31. PubMed ID: 21498929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
    Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
    Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
    Byrd C; Mowrey KA
    Am J Health Syst Pharm; 2010 Dec; 67(23):2038-42. PubMed ID: 21098376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC
    Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
    Rodríguez A; Reviriego J; Polavieja P; Mesa J
    Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
    Yu Y; Li Y; Fan J; Wang Y; Yu H; Wang C; Liao Z; Gao H; Zhao W
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):117-20. PubMed ID: 15600200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.